Related Experiment Video
Updated: Aug 27, 2025
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
3.7K
Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
Alaa Embaby1, Lisanne van Merendonk2, Neeltje Steeghs1
1Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Frontiers in Oncology
|October 3, 2022
Summary
Non-selective beta-blockers show promise for angiosarcoma treatment. Drugs with intrinsic sympathomimetic activity or vasodilator effects, like labetalol, may reduce cardiovascular risks in patients without heart conditions.
Area of Science:
- Pharmacology
- Oncology
- Cardiology
Background:
- Angiosarcoma treatment options are limited.
- Beta-blockers are being investigated as a novel therapeutic strategy for angiosarcoma.
- Most angiosarcoma patients lack cardiovascular comorbidities, necessitating careful drug selection.
Purpose of the Study:
- To determine the optimal pharmacological properties of beta-blockers for angiosarcoma treatment.
- To identify beta-blockers that maximize efficacy while minimizing cardiovascular adverse events in angiosarcoma patients.
Main Methods:
- Review of in vitro data regarding beta-blocker effectiveness in angiosarcoma.
- Analysis of pharmacological properties, including intrinsic sympathomimetic activity and vasodilator effects.
- Examination of existing clinical data on beta-blocker use in angiosarcoma.
Main Results:
- Non-selective beta-blockers are preferred for maximizing potential effectiveness in angiosarcoma based on in vitro data.
- Beta-blockers with intrinsic sympathomimetic activity or vasodilator effects (e.g., labetalol, pindolol, carvedilol) are suggested to minimize cardiovascular risks.
- Currently, only propranolol has available efficacy data, with one reported case of carvedilol use.
Conclusions:
- Non-selective beta-blockers are a promising avenue for angiosarcoma therapy.
- Labetalol, pindolol, or carvedilol are potential candidates for future studies to mitigate cardiovascular adverse events.
- Further research is needed to evaluate the efficacy and safety of specific beta-blockers in angiosarcoma patients without cardiovascular comorbidities.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
555
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
555
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
720
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
720
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
932
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
932
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
971
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
971
01:28Antihypertensive Drugs: Types of β-Blockers
823
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
823
01:22Heart Failure Drugs: β-Blockers
418
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
418